Arcus Biosciences (RCUS) Return on Capital Employed (2018 - 2026)

Arcus Biosciences' Return on Capital Employed history runs 9 years deep, the most recent figure standing at 46.33% for Q1 2026.

• In Q1 2026, Return on Capital Employed fell 198.0% year-over-year to 46.33%; the TTM figure through Mar 2026 stood at 46.33% (down 198.0% YoY), while the FY2025 annual figure was 42.26%, down 545.0% from the prior year.
• Return on Capital Employed was 46.33% for Q1 2026 at Arcus Biosciences, up from 46.76% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 5.96% in Q3 2022 to a low of 47.5% in Q3 2025.
• Historically, Return on Capital Employed has averaged 27.87% across 5 years, with a median of 30.72% in 2024.
• The sharpest annual moves came in 2022 and 2023: Return on Capital Employed jumped 4436 bps in 2022, then tumbled 3809 bps in 2023.
• A 5-year view of Return on Capital Employed shows it stood at 24.27% in 2022, then sank by 46 bps to 35.45% in 2023, then increased by 7 bps to 33.03% in 2024, then plunged by 42 bps to 46.76% in 2025, then advanced by 1 bps to 46.33% in 2026.
• The last three Return on Capital Employed figures came in at 46.33% (Q1 2026), 46.76% (Q4 2025), and 47.5% (Q3 2025), per Business Quant data.